Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPG in First-line DLBCL and HGBL
NCT07502872Phase 2Not yet recruiting
- Sponsor
- Brown University
- Start
- Nov 2026
- Primary completion
- Jan 2030
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab, polatuzumab vedotin, glofitamab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), sponsored by Brown University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tafasitamabpolatuzumab vedotinglofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT07502872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502872.